Business Context and Reporting Period
Company: Disc Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 25, 2023
Reporting Period: Event date of January 25, 2023.
Context: The Company, an emerging growth company incorporated in Delaware, reported the entry into a material definitive agreement to facilitate the sale of its common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering agreement.
Material Changes and Agreements
- Sales Agreement: Entered into a Sales Agreement with SVB Securities LLC on January 25, 2023.
- Offering Capacity: The Company may issue and sell shares of common stock (Placement Shares) with an aggregate offering price of up to $100.0 million.
- Method of Sale: Shares will be sold via an "at the market" offering through SVB Securities acting as sales agent, potentially on the Nasdaq Global Market.
- Compensation: The Company will pay SVB Securities a commission of up to 3.0% of the gross sales proceeds.
- Registration: The offering is pursuant to a prospectus supplement to Form S-3 (File No. 333-269272), which became effective on January 24, 2023.
- Obligation: The Company is not obligated to make any sales of Placement Shares under the Agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing states that SVB Securities will use commercially reasonable efforts to sell shares based on instructions from the Company, including price or size limits. The agreement includes customary representations, warranties, and covenants, and the Company has agreed to indemnify SVB Securities against certain liabilities.
Risks and Contingencies: The offering will terminate upon the earlier of the sale of all Placement Shares or termination of the Agreement. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current market price of Disc Medicine common stock (Symbol: IRON) to assess potential dilution from the $100 million offering.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Check the Company's Form S-3 (File No. 333-269272) for the prospectus supplement details.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the Company's current cash position in its most recent 10-K or 10-Q to understand the necessity of this capital raise.